<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864162</url>
  </required_header>
  <id_info>
    <org_study_id>20-678-1G</org_study_id>
    <nct_id>NCT00864162</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions</brief_title>
  <official_title>A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Ramipril10 mg Capsules Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the rate of absorption and oral bioavailability of a test formulation of
      Ramipril10 mg Capsules manufactured by Purepac Pharmaceutical Company to an equivalent oral
      dose of the commercially available reference product Atlace® manufactured by Monarch
      Pharmaceuticals Inc. administrated to healthy subjects after a 10-hour overnight fast
      followed by a high-calorie, high-fat breakfast meal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: A single-dose, open-label, randomized, two-period
      crossover study

      Official Title: A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of
      Ramipril10 mg Capsules Under Fed Conditions

      Further study details as provided by Actavis Elizabeth LLC:

      Primary Outcome Measures:

      Rate and Extend of Absorption
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramipril10 mg Capsules, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atlace® 10 mg capsules, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril10 mg Capsules, single dose</intervention_name>
    <description>A: Experimental Subjects received Purepac formulated products under fed conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Ramipril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atlace® 10 mg capsules, single dose</intervention_name>
    <description>B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Ramipril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be a male or non-pregnant, non-breast-feeding female.

          -  Subject must be between 18 and 55 years of age inclusive.

          -  Subject's body weight should be within ±15% of the ideal body weight for their height
             and estimated frame based on the Metropolitan Life Insurance Company Table.

          -  Female subjects of childbearing potential --- not surgically sterile or at least two
             years postmenopausal-- must agree to utilize one of the following forms of
             contraception, if sexually active with a male partner, from screening through
             completion of the study. Approved forms of contraception are abstinence, hormonal
             (oral, implant, transdermal or injection), double barrier (condom and diaphragm with
             spermicide), IUD, or vasectomized partner (6 months minimum).

          -  Subject must voluntarily consent to participate in this study and provide their
             written informed consent prior to completion of any study-specific procedures.

          -  Subject is willing and able to remain in the research center for the entire duration
             of each confinement period and return to the research center for any outpatient
             visits.

        Exclusion Criteria:

          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,
             neurologic, oncologic or psychiatric disease or any other condition which, in the
             opinion of the Investigator would jeopardize the safety of the subject or the validity
             of the study results.

          -  Has a clinically significant abnormal finding on the physical exam, medical history or
             clinical laboratory results at screening.

          -  History or presence of allergic or adverse response to the study drug or related
             drugs.

          -  Has been on a significantly abnormal diet during the four weeks preceding the first
             dose of study medication.

          -  Has donated blood or plasma within 30 days prior to the first dose of study
             medication.

          -  Has participated in another clinical trial within 30 days prior to first dose of study
             medication.

          -  Has used any over-the-counter (OTC) medication including vitamins, within 7 days prior
             to the first dose of study medication.

          -  Has used any prescription medication, except hormonal contraceptive or hormonal
             replacement therapy, within 7 days prior to the first dose of study medication.

          -  Has been treated with any known enzyme altering drugs such as barbiturates,
             phenothiazines, cimetidine, carbamazepine, etc., within 30 days prior to the first
             dose of study medication.

          -  Has smoked or used tobacco products within 60 days prior to the first dose of study
             medication.

          -  Has a history of substance abuse (including alcohol) in the past 5 years

          -  Is female with a positive pregnancy test.

          -  Positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines,
             cocaine, cannabinoids, opiates).

          -  Has had a positive test for, or has been treated for hepatitis B, hepatitis C or HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel V. Freeland,, D.O., CCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEDRA Clinical Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CEDRA Clinical Research, LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://chem.sis.nlm.nih.gov/chemidplus/ProxyServlet?objectHandle=DBMaint&amp;actionHandle=default&amp;nextPage=jsp/chemidlite/ResultScreen.jsp&amp;TXTSUPERLISTID=087333195</url>
    <description>RAMIPRIL</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Ramipril</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

